Redcare Pharmacy Aktie 34117753 / NL0012044747
Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Orderbuch | Analysen | |||||
Historisch |
15.07.2025 12:12:43
|
EQS-News: Redcare Pharmacy’s CardLink solution for e-Rx redemption extended by gematik, enabling a smooth transition to the next generation technology.
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Regulatory Approval
Redcare Pharmacy’s CardLink solution for e-Rx redemption extended by gematik, enabling a smooth transition to the next generation technology. Sevenum, the Netherlands, 15 July 2025. Today Redcare Pharmacy was notified by its technology partner eHealth Experts that an extension until 31 January 2027 for its CardLink product license has been received. Redcare’s CardLink solution has been available in the Shop Apotheke app since May 2024, allowing patients in Germany to redeem their prescriptions digitally. With the extension of its CardLink solution, Redcare’s access to the German e-prescription market continues and remains secured during the transition to the new Proof of Patient Presence (PoPP) infrastructure. This next generation technology (PoPP) will continue to support electronic health card (eGK) redemption without PIN. Additionally, PoPP will provide an even higher standard of security and could offer more authentication options, such as biometric verification via Face ID or fingerprint. The new functionalities are expected to become available in late 2026. Redcare Pharmacy’s CEO, Olaf Heinrich comments: “The extension of CardLink is a logical step for a smooth transition to the PoPP infrastructure. We are looking forward to the introduction of this new national standard, which will make prescription redemption even more convenient for patients.”
Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
15.07.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Redcare Pharmacy N.V. |
Erik de Rodeweg 11-13 | |
5975 WD Sevenum | |
Netherlands | |
Phone: | 0800 - 200 800 300 |
Fax: | 0800 - 90 70 90 20 |
E-mail: | investors@redcare-pharmacy.com |
Internet: | www.redcare-pharmacy.com |
ISIN: | NL0012044747, DE000A19Y072 |
WKN: | A2AR94, A19Y072 |
Indices: | MDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2169990 |
End of News | EQS News Service |
|
2169990 15.07.2025 CET/CEST
Nachrichten zu Redcare Pharmacy (ex Shop Apotheke)
05.09.25 |
MDAX aktuell: MDAX letztendlich mit positivem Vorzeichen (finanzen.ch) | |
05.09.25 |
Optimismus in Frankfurt: MDAX zeigt sich am Nachmittag fester (finanzen.ch) | |
05.09.25 |
Handel in Frankfurt: MDAX klettert (finanzen.ch) | |
05.09.25 |
Optimismus in Frankfurt: Anleger lassen MDAX zum Start steigen (finanzen.ch) | |
04.09.25 |
Börse Frankfurt: MDAX am Donnerstagnachmittag in der Gewinnzone (finanzen.ch) | |
04.09.25 |
Anleger in Frankfurt halten sich zurück: MDAX verbucht zum Handelsstart Verluste (finanzen.ch) | |
03.09.25 |
Starker Wochentag in Frankfurt: MDAX zum Ende des Mittwochshandels mit Zuschlägen (finanzen.ch) | |
03.09.25 |
XETRA-Handel: MDAX am Mittwochnachmittag im Plus (finanzen.ch) |
Analysen zu Redcare Pharmacy (ex Shop Apotheke)
03.09.25 | Redcare Pharmacy Buy | Jefferies & Company Inc. | |
29.08.25 | Redcare Pharmacy Buy | Deutsche Bank AG | |
28.08.25 | Redcare Pharmacy Buy | Jefferies & Company Inc. | |
05.08.25 | Redcare Pharmacy Buy | Jefferies & Company Inc. | |
31.07.25 | Redcare Pharmacy Buy | Deutsche Bank AG |
KI Aktien – Gewinner der Digitalisierung – Wall Street Live mit Tim Schäfer
In dieser Folge sprechen wir mit Tim Schäfer live aus New York über den aktuellen Stand der KI-Aktien. Sind die Kurse von Nvidia, Microsoft, Meta, Amazon, Alphabet und Apple noch gerechtfertigt – oder stehen wir kurz vor einer Spekulationsblase?
📈 Tim analysiert die Zahlen, Investitionen und Bewertungen der grossen Tech-Konzerne und zeigt, wie viel Kapital derzeit in KI-Infrastruktur fliesst. Zudem diskutieren wir, welche Randbereiche vom KI-Boom profitieren könnten – etwa Rechenzentren, Stromversorger oder Hardwarehersteller.
Themen im Video:
🔹Die „Magnificent 7“ im Check: Meta, Microsoft, Nvidia, Amazon, Alphabet, Apple
🔹Investitionen in KI: 71 Mrd. bei Meta, 120 Mrd. bei Microsoft
🔹Nvidia: Marktführer, aber extrem teuer
🔹Apple: Aufholjagd oder zu spät dran?
🔹Gefahr einer KI-Blase?
🔹Welche Alternativen bieten sich für Langfristinvestoren?
🔹Rechenzentren, Energieanbieter & Zulieferer im Fokus
🔹Wie Tim mit Rücksetzern und Seitwärtsphasen umgeht
🔹Erste Anzeichen für eine neue Superintelligenz?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach US-Arbeitsmarktzahlen: SMI geht etwas leichter ins Wochenende -- DAX letztlich in Rot -- Gewinnmitnahmen an den US-Börsen -- Märkte in Asien schliessen mit AufschlägenDer heimische Leitindex präsentierte sich am Freitag etwas schwächer. Am deutschen Aktienmarkt ging es abwärts. Die US-Börsen gaben nach neuen Rekorden nach. In Fernost dominierten die Käufer.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |